Page last updated: 2024-08-26

tretazicar and Granulocytic Leukemia, Chronic

tretazicar has been researched along with Granulocytic Leukemia, Chronic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Caraher, MC; Dunstan, MS; Leys, D; Nolan, KA; Scott, KA; Stratford, IJ	1

Other Studies

1 other study(ies) available for tretazicar and Granulocytic Leukemia, Chronic

Article	Year
In silico screening reveals structurally diverse, nanomolar inhibitors of NQO2 that are functionally active in cells and can modulate NF-κB signaling. Molecular cancer therapeutics, 2012, Volume: 11, Issue:1 Topics: Animals; Aziridines; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrophages; Mice; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Quinone Reductases; RNA Interference; RNA, Small Interfering; Signal Transduction; Structure-Activity Relationship; Transcription, Genetic; Tumor Necrosis Factor-alpha	2012

Article

Year

In silico screening reveals structurally diverse, nanomolar inhibitors of NQO2 that are functionally active in cells and can modulate NF-κB signaling.

Molecular cancer therapeutics, 2012, Volume: 11, Issue:1

Topics: Animals; Aziridines; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrophages; Mice; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Quinone Reductases; RNA Interference; RNA, Small Interfering; Signal Transduction; Structure-Activity Relationship; Transcription, Genetic; Tumor Necrosis Factor-alpha

2012